{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:37:00Z","timestamp":1789504620222,"version":"build-2803163510"},"reference-count":89,"publisher":"Begell House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2025]]},"abstract":"<p>Calcineurin inhibitors (CNIs) are key in immunosuppressive therapy for organ transplantation and autoimmune diseases by modulating T cell activation. This review details how CNIs inhibit T cell receptor signaling, cytokine production, and T cell differentiation by binding to intracellular proteins, thus preventing the activation of NFAT, a critical transcription factor. The clinical benefits of CNIs include preventing graft rejection and controlling autoimmune responses, but they also have significant side effects such as nephrotoxicity, neurotoxicity, hypertension, hyperlipidemia, and increased risk of infections and malignancies. Optimizing CNI use involves developing safer versions, personalizing regimens, and combining therapies to lower doses and reduce side effects. Understanding CNIs' interactions with T cells can improve therapy outcomes and guide the creation of targeted treatments. Effective patient monitoring and management are essential to mitigate toxicities. Future research should focus on CNIs' pharmacodynamics and pharmacokinetics in developing next-generation immunosuppressants, and personalized and combination therapies to enhance safety and efficacy, ultimately improving patient outcomes and quality of life.<\/p>","DOI":"10.1615\/critrevimmunol.2025057969","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:20:38Z","timestamp":1747225238000},"page":"43-56","source":"Crossref","is-referenced-by-count":7,"title":["Understanding the Impact of Calcineurin Inhibitors on T Cell Regulation: Mechanisms and Clinical Implications"],"prefix":"10.1615","volume":"45","author":[{"given":"Vijaykumar D.","family":"Nimbarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya S.","family":"Sonak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharda","family":"Ishwarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Farouk SS, Rein JL. The many faces of calcineurin inhibitor toxicity - what the FK? Adv Chronic Kidney Dis. 2020;27:56-66.","DOI":"10.1053\/j.ackd.2019.08.006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Prasad N, Manjunath R, Rangaswamy D, Jaiswal A, Agarwal V, Bhadauria D, Kaul A, Sharma R, Gupta A. Efficacy and safety of cyclosporine versus tacrolimus in steroid and cyclophosphamide resistant nephrotic syndrome: A prospective study. Indian J Nephrol. 2018;28(1): 46-52.","DOI":"10.4103\/ijn.IJN_240_16"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Mulero MC, Aubareda A, Orzaez M, Messeguer J, Serrano-Candelas E, Martinez-Hoyer S, Messeguer A, Perez-Paya E, Perez-Riba M. Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) signaling pathway with a regulator of calcineurin-derived peptide without affecting general calcineurin phosphatase activity. J Biol Chem. 2009;284(14):9394-401.","DOI":"10.1074\/jbc.M805889200"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Ingulli E. Mechanism of cellular rejection in transplantation. Pediatr Nephrol. 2010;25:61-74.","DOI":"10.1007\/s00467-008-1020-x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34-50.","DOI":"10.1038\/cr.2009.139"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Sig Transduct Target Ther. 2023;8:235.","DOI":"10.1038\/s41392-023-01471-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125:S3-S23.","DOI":"10.1016\/j.jaci.2009.12.980"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Oparaugo NC, Ouyang K, Nguyen NPN, Nelson AM, Agak GW. Human regulatory T Cells: Understanding the role of Tregs in select autoimmune skin diseases and post-transplant nonmelanoma skin cancers. IJMS. 2023;24:1527.","DOI":"10.3390\/ijms24021527"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Maldini CR, Ellis GI, Riley JL. CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol. 2018;18:605-16.","DOI":"10.1038\/s41577-018-0042-2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651-68.","DOI":"10.1038\/s41577-020-0306-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Effer B, Perez I, Ulloa D, Mayer C, Munoz F, Bustos D, Rojas C, Manterola C, Vergara-G\u00f3mez L, Dappolonnio C, Weber H. Therapeutic targets of monoclonal antibodies used in the treatment of cancer: Current and emerging. Biomedicines. 2023;11(7):2086.","DOI":"10.3390\/biomedicines11072086"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Ume AC, Pugh JM, Kemp MG, Williams CR. Calcineurin inhibitor (CNI)-associated skin cancers: New insights on exploring mechanisms by which CNIs downregulate DNA repair machinery. Photoderm Photoimm Photomed. 2020;36:433-40.","DOI":"10.1111\/phpp.12600"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Vaeth M, Feske S. NFAT control of immune function: New frontiers for an abiding trooper. F1000Res. 2018;7:260.","DOI":"10.12688\/f1000research.13426.1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Chen J, Huang F, Hou Y, Lin X, Liang R, Hu X, Zhao J, Wang J, Olsen N, Zheng SG. TGF-\u03b2-induced CD4+ FoxP3+ regulatory T cell-derived extracellular vesicles modulate Notch1 signaling through miR-449a and prevent collagen-induced arthritis in a murine model. Cell Mol Immunol. 2021;18(11):2516-29.","DOI":"10.1038\/s41423-021-00764-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Duneton C, Winterberg PD, Ford ML. Activation and regulation of alloreactive T cell immunity in solid organ transplantation. Nat Rev Nephrol. 2022;18:663-76.","DOI":"10.1038\/s41581-022-00600-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Shah K, Al-Haidari A, Sun J, Kazi JU. T cell receptor (TCR) signaling in health and disease. Sig Transduct Target Ther. 2021;6:412.","DOI":"10.1038\/s41392-021-00823-w"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Courtney AH, Lo WL, Weiss A. TCR signaling: Mechanisms of initiation and propagation. Biochem Sci. 2018;43:108-23.","DOI":"10.1016\/j.tibs.2017.11.008"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Aguilar LM, Vico-Barranco I, Arbulo-Echevarria MM, Aguado E. A story of kinases and adaptors: The role of Lck, ZAP-70 and LAT in switch panel governing T-cell development and activation. Biology. 2023;12:1163.","DOI":"10.3390\/biology12091163"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: Angels versus demons in a heart-breaking tale. Physiol Rev. 2010;90:1507-46.","DOI":"10.1152\/physrev.00054.2009"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-kB pathway for the therapy of diseases: Mechanism and clinical study. Sig Transduct Target Ther. 2020;5:209.","DOI":"10.1038\/s41392-020-00312-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, Sato N, Kaiser A, Heinrichs C, Klebanoff CA, Tagaya Y, Restifo NP. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol. 2006;176(9):5255-66.","DOI":"10.4049\/jimmunol.176.9.5255"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Yang PC, Jafri MS. Ca2+ signaling in T lymphocytes: The interplay of the endoplasmic reticulum, mitochondria, membrane potential, and CRAC channels on transcription factor activation. Heliyon. 2020;6:e03526.","DOI":"10.1016\/j.heliyon.2020.e03526"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Alothaid H, Aldughaim MSK, Alamri SS, Alrahimi JSM, Al-Jadani SH. Role of calcineurin biosignaling in cell secretion and the possible regulatory mechanisms. Saudi J Biol Sci. 2021;28:116-24.","DOI":"10.1016\/j.sjbs.2020.08.042"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Mancini M, Toker A. NFAT proteins: Emerging roles in cancer progression. Nat Rev Cancer. 2009;9:810-20.","DOI":"10.1038\/nrc2735"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Lee W, Lee GR. Transcriptional regulation and development of regulatory T cells. Exp Mol Med. 2018;50:e456-e456.","DOI":"10.1038\/emm.2017.313"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Okamura H, Aramburu J, Garc\u00eda-Rodr\u00edguez C, Viola JP, Raghavan A, Tahiliani M, Zhang X, Qin J, Hogan PG, Rao A. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell. 2000;6(3):539-50.","DOI":"10.1016\/S1097-2765(00)00053-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, Zeng C, Zhou T, Zhang J. NF-\u00ce\u00baB in biology and targeted therapy: New insights and translational implications. Sig Transduct Target Ther. 2024;9(1):53.","DOI":"10.1038\/s41392-024-01757-9"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Zanoni I, Granucci F. Regulation and dysregulation of innate immunity by NFAT signaling downstream of pattern recognition receptors (PRRs). Eur J Immunol. 2012;42:1924-31.","DOI":"10.1002\/eji.201242580"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Yilmaz DE, Kirschner K, Demirci H, Himmerkus N, Bachmann S, Mutig K. Immunosuppressive calcineurin inhibitor cyclosporine A induces proapoptotic endoplasmic reticulum stress in renal tubular cells. J Biol Chem. 2022;298:101589.","DOI":"10.1016\/j.jbc.2022.101589"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Zhou Y, Quan G, Liu Y, Shi N, Wu Y, Zhang R, Gao X, Luo L. The application of Interleukin-2 family cytokines in tumor immunotherapy research. Front Immunol. 2023;14:1090311.","DOI":"10.3389\/fimmu.2023.1090311"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Wei X, Li H, Zhang Y, Li C, Li K, Ai K, Yang J. Ca2+-calcineurin axis-controlled NFAT nuclear translocation is crucial for optimal T cell immunity in an early vertebrate. J Immunol. 2020;204(3):569-85.","DOI":"10.4049\/jimmunol.1901065"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Qian Z, Dougherty PG, Liu T, Oottikkal S, Hogan PG, Hadad CM, Pei D. Structure-based optimization of a peptidyl inhibitor against calcineurin-nuclear factor of activated T cell (NFAT) interaction. J Med Chem. 2014;57(18):7792-7.","DOI":"10.1021\/jm500743t"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Sharma S, Findlay GM, Bandukwala HS, Oberdoerffer S, Baust B, Li Z, Schmidt V, Hogan PG, Sacks DB, Rao A. Dephosphorylation of the nuclear factor of activated T cells (NFAT) transcription factor is regulated by an RNA-protein scaffold complex. Proc Natl Acad Sci. 2011;108(28):11381-6.","DOI":"10.1073\/pnas.1019711108"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Bachmann MF, Oxenius A. Interleukin 2: From immunostimulation to immunoregulation and back again. EMBO Rep. 2007;8:1142-48.","DOI":"10.1038\/sj.embor.7401099"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Bentley ER, Little SR. Local delivery strategies to restore immune homeostasis in the context of inflammation. Adv Drug Deliv Rev. 2021;178:113971.","DOI":"10.1016\/j.addr.2021.113971"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Macian F. NFAT proteins: Key regulators of T-cell development and function. Nat Rev Immunol. 2005;5: 472-84.","DOI":"10.1038\/nri1632"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Jin P, Wang E, Provenzano M, Deola S, Selleri S, Ren J, Voiculescu S, Stroncek D, Panelli MC, Marincola FM. Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med. 2006;4:1-23.","DOI":"10.1186\/1479-5876-4-26"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Singer M, Elsayed AM, Husseiny MI. Regulatory T-cells: The face-off of the immune balance. Front Biosci (Landmark Ed). 2024;29:377.","DOI":"10.31083\/j.fbl2911377"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Ponticelli C, Reggiani F, Moroni G. Old and new calcineurin inhibitors in lupus nephritis. JCM. 2021;10:4832.","DOI":"10.3390\/jcm10214832"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Braza F, Durand M, Degauque N, Brouard S. Regulatory T cells in kidney transplantation: New directions? Am J Transplant. 2015;15:2288-300.","DOI":"10.1111\/ajt.13395"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Ochayon DE, Waggoner SN. The effect of unconventional cytokine combinations on NK-cell responses to viral infection. Front Immunol. 2021;12:645850.","DOI":"10.3389\/fimmu.2021.645850"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Alspach E, Lussier DM, Schreiber RD. Interferon \u03b3 and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb Perspect Biol. 2019;11:a028480.","DOI":"10.1101\/cshperspect.a028480"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Campe J, Ullrich E. T helper cell lineage-defining transcription factors: Potent targets for specific GVHD therapy? Front Immunol. 2022;12:806529.","DOI":"10.3389\/fimmu.2021.806529"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Pilat N, Steiner R, Sprent J. Treg Therapy for the induction of immune tolerance in transplantation-not lost in translation? IJMS. 2023;24:1752.","DOI":"10.3390\/ijms24021752"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, Sherwani K, Ettl T, Mayer S, Falkner F, Kilian K. Immune modulation in transplant medicine: A comprehensive review of cell therapy applications and future directions. Front Immunol. 2024;15:1372862.","DOI":"10.3389\/fimmu.2024.1372862"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine. 2015;75:14-24.","DOI":"10.1016\/j.cyto.2015.05.010"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2023;23:38-54.","DOI":"10.1038\/s41577-022-00746-9"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Bosnjak B, Stelzmueller B, Erb KJ, Epstein MM. Treatment of allergic asthma: Modulation of Th2 cells and their responses. Respir Res. 2011;12:114.","DOI":"10.1186\/1465-9921-12-114"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Muckenhuber M, Mengrelis K, Weijler AM, Steiner R, Kainz V, Buresch M, Regele H, Derdak S, Kubetz A, Wekerle T. IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice. Nat Commun. 2024;15:4309.","DOI":"10.1038\/s41467-024-48574-w"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Hardtke-Wolenski M, Landwehr-Kenzel S. Tipping the balance in autoimmunity: Are regulatory T cells the cause, the cure, or both? Mol Cell Pediatr. 2024;11:3.","DOI":"10.1186\/s40348-024-00176-8"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Martin-Moreno PL, Tripathi S, Chandraker A. Regulatory T cells and kidney transplantation. CJASN. 2018;13:1760-4.","DOI":"10.2215\/CJN.01750218"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Kumar P, Saini S, Khan S, Surendra Lele S, Prabhakar BS. Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells. Cell Immunol. 2019;339:41-9.","DOI":"10.1016\/j.cellimm.2018.09.008"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Wang Y, Ullah MA, Waltner OG, Bhise SS, Ensbey KS, Schmidt CR, Legg SR, Sekiguchi T, Nelson EL, Kuns RD, Nemychenkov NS. Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD. J Clin Invest. 2024;134(11).","DOI":"10.1172\/JCI170125"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Podest\u00e0 MA, Remuzzi G, Casiraghi F. Mesenchymal stromal cells for transplant tolerance. Front Immunol. 2019;10:1287.","DOI":"10.3389\/fimmu.2019.01287"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Hussain Y, Khan H. Immunosuppressive drugs. In: Encyclopedia of Infection and Immunity [Internet]. Elsevier; 2022 [cited 2024 Jul 20];726-40. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128187319000689.","DOI":"10.1016\/B978-0-12-818731-9.00068-9"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Halloran PF, Afrouzian M, Ramassar V, Urmson J, Zhu LF, Helms LM, Solez K, Kneteman NM. Interferon-camma acts directly on rejecting renal allografts to prevent graft necrosis. Am J Pathol. 2001;158(1):215-26.","DOI":"10.1016\/S0002-9440(10)63960-0"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Al-Naimi M, Rasheed H, Hussien N, Al-Kuraishy H, Al-Gareeb A. Nephrotoxicity: Role and significance of renal biomarkers in the early detection of acute renal injury. J Adv Pharm Technol Res. 2019;10:95.","DOI":"10.4103\/japtr.JAPTR_336_18"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs. 2019;79:365-79.","DOI":"10.1007\/s40265-019-1064-1"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Latha VA, Mondu SSD, Dinesh Eshwar M, Polala AR, Nandanavanam S, Dodda S. Dyslipidemia among diabetes mellitus patients: A case-control study from a tertiary care hospital in South India. Cureus [Internet]. 2023 [cited 2024 Jul 20]. Available from: https:\/\/www.cureus.com\/articles\/136245-dyslipidemia-among-diabetes-mellitus-patients-a-case-control-study-from-a-tertiary-care-hospital-in-south-india.","DOI":"10.7759\/cureus.35625"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Jeon JY, Han-Bit S, Park BH, Lee N, Kim HJ, Kim DJ, Lee KW, Han SJ. Impact of post-transplant diabetes mellitus on survival and cardiovascular events in kidney transplant recipients. Endocrinol Metab. 2023;38(1):139-45.","DOI":"10.3803\/EnM.2022.1594"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Szumilas K, Wilk A, Wisniewski P, Gimpel A, Dziedziejko V, Kipp M, Pawlik A. Current status regarding immunosuppressive treatment in patients after renal transplantation. Int J Mol Sci. 2023;24(12):10301.","DOI":"10.3390\/ijms241210301"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Karpe KM, Talaulikar GS, Walters GD. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. Cochrane Kidney and Transplant Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2017 [cited 2024 Jul 20]. Available from: http:\/\/doi.wiley. com\/10.1002\/14651858.CD006750.pub2.","DOI":"10.1002\/14651858.CD006750.pub2"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Dobrek L. A Synopsis of current theories on drug-induced nephrotoxicity. Life. 2023;13:325.","DOI":"10.3390\/life13020325"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: Objectives and interim result. Clin J Am Soc Nephrol. 2008;3:S101-16.","DOI":"10.2215\/CJN.03510807"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Akiyama S, Steinberg JM, Kobayashi M, Suzuki H, Tsuchiya K. Pregnancy and medications for inflammatory bowel disease: An updated narrative review. World J Clin Cases. 2023;11:1730-40.","DOI":"10.12998\/wjcc.v11.i8.1730"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Ohmes J, Comd\u00fchr S, Akbarzadeh R, Riemekasten G, Humrich JY. Dysregulation and chronicity of pathogenic T cell responses in the pre-diseased stage of lupus. Front Immunol. 2022;13:1007078.","DOI":"10.3389\/fimmu.2022.1007078"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Ivashkiv LB. IFN\u03b3: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18:545-58.","DOI":"10.1038\/s41577-018-0029-z"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Rana S, Maharjan S, Sookdeo SD, Schmidt P. Pain management in multiple myeloma patients: A literature review. Cureus [Internet]. 2024 [cited 2024 Jul 20]. Available from: https:\/\/www.cureus.com\/articles\/233819-pain-management-in-multiple-myeloma-patients-a-literature-review.","DOI":"10.7759\/cureus.55975"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Sabat R, Wolk K, Loyal L, D\u00f6cke WD, Ghoreschi K. T cell pathology in skin inflammation. Semin Immunopathol. 2019;41:359-77.","DOI":"10.1007\/s00281-019-00742-7"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Joosse ME, Charbit-Henrion F, Boisgard R, Lindenbergh-Kortleve DJ, Costes LM, Nugteren S, Guegan N, Parlato M, Veenbergen S, Malan V, Nowak JK. Duplication of the IL2RA locus causes excessive IL-2 signaling and may predispose to very early onset colitis. Mucosal Immunol. 2021;14(5):1172-82.","DOI":"10.1038\/s41385-021-00423-5"},{"key":"72","doi-asserted-by":"crossref","unstructured":"Otte ML, Lama Tamang R, Papapanagiotou J, Ahmad R, Dhawan P, Singh AB. Mucosal healing and inflammatory bowel disease: Therapeutic implications and new targets. World J Gastroenterol. 2023;29:1157-72.","DOI":"10.3748\/wjg.v29.i7.1157"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Rosenblum MD, Gratz IK, Paw JS, Abbas AK. Treating human autoimmunity: Current practice and future prospects. Sci Transl Med [Internet]. 2012 [cited 2024 Jul 15];4. Available from: https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.3003504.","DOI":"10.1126\/scitranslmed.3003504"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Malhotra D, Jethwani P. Preventing rejection of the kidney transplant. JCM. 2023;12:5938.","DOI":"10.3390\/jcm12185938"},{"key":"75","doi-asserted-by":"crossref","unstructured":"Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, Mak T, Marshall A, Frank B, Malik RA, Alam U. Chemotherapy-induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment. Oncol Ther. 2021:1-66.","DOI":"10.1007\/s40487-021-00168-y"},{"key":"76","doi-asserted-by":"crossref","unstructured":"Hobson EV, Craven I, Blank SC. Posterior reversible encephalopathy syndrome: A truly treatable neurologic illness. Perit Dial Int. 2012;32:590-4.","DOI":"10.3747\/pdi.2012.00152"},{"key":"77","doi-asserted-by":"crossref","unstructured":"Bamgbola O. Metabolic consequences of modern immunosuppressive agents in solid organ transplantation. Ther Adv Endocrinol. 2016;7:110-27.","DOI":"10.1177\/2042018816641580"},{"key":"78","doi-asserted-by":"crossref","unstructured":"Gill JS. Cardiovascular disease in transplant recipients: Current and future treatment strategies. Clin J Am Soc Nephrol. 2008;3:S29-S37.","DOI":"10.2215\/CJN.02690707"},{"key":"79","doi-asserted-by":"crossref","unstructured":"Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75:235-51.","DOI":"10.1037\/amp0000517"},{"key":"80","doi-asserted-by":"crossref","unstructured":"Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, Bittleman D, Cruz D, Endre Z, Fitzgerald RL, Forni L. Acute kidney disease and renal recovery: Consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13(4):241-57.","DOI":"10.1038\/nrneph.2017.2"},{"key":"81","doi-asserted-by":"crossref","unstructured":"Goetz LH, Schork NJ. Personalized medicine: Motivation, challenges, and progress. Fertil Steril. 2018;109:952-63.","DOI":"10.1016\/j.fertnstert.2018.05.006"},{"key":"82","doi-asserted-by":"crossref","unstructured":"Hamdy AF, Bakr MA, Ghoneim MA. Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. J Am Soc Nephrol. 2008;19:1225-32.","DOI":"10.1681\/ASN.2007091001"},{"key":"83","doi-asserted-by":"crossref","unstructured":"Bhati D, Deogade MS, Kanyal D. Improving patient outcomes through effective hospital administration: A comprehensive review. Cureus [Internet]. 2023 [cited 2024 Jul 20]; Available from: https:\/\/www.cureus.com\/articles\/197936-improving-patient-outcomes-through-effective-hospital-administration-a-comprehensive-review.","DOI":"10.7759\/cureus.47731"},{"key":"84","doi-asserted-by":"crossref","unstructured":"Chapman NM, Chi H. mTOR signaling, Tregs and immune modulation. Immunotherapy. 2014;6:1295-311.","DOI":"10.2217\/imt.14.84"},{"key":"85","doi-asserted-by":"crossref","unstructured":"Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008;1:27-36.","DOI":"10.1007\/s12154-008-0003-5"},{"key":"86","doi-asserted-by":"crossref","unstructured":"Gatault P, Lebranchu Y. Conversion to mTOR-inhibitor-based immunosuppression: Which patients and when? Transplant Res. 2013;2:S3.","DOI":"10.1186\/2047-1440-2-S1-S3"},{"key":"87","doi-asserted-by":"crossref","unstructured":"El Hage A, Dormond O. Combining mTOR inhibitors and T cell-based immunotherapies in cancer treatment. Cancers. 2021;13:1359.","DOI":"10.3390\/cancers13061359"},{"key":"88","doi-asserted-by":"crossref","unstructured":"Ali ES, Mitra K, Akter S, Ramproshad S, Mondal B, Khan IN, Islam MT, Sharifi-Rad J, Calina D, Cho WC. Recent advances and limitations of mTOR inhibitors in the treatment of cancer. Cancer Cell Int. 2022;22(1):284.","DOI":"10.1186\/s12935-022-02706-8"},{"key":"89","doi-asserted-by":"crossref","unstructured":"Ferreira Do Couto ML, Fonseca S, Pozza DH. Pharmacogenetic approaches in personalized medicine for postoperative pain management. Biomedicines. 2024;12:729.","DOI":"10.3390\/biomedicines12040729"},{"key":"90","doi-asserted-by":"crossref","unstructured":"Alhassani RY, Bagadood RM, Balubaid RN, Barno HI, Alahmadi MO, Ayoub NA. Drug therapies affecting renal function: An overview. Cureus [Internet]. 2021 [cited 2024 Jul 20]. Available from: https:\/\/www.cureus.com\/articles\/74703-drug-therapies-affecting-renal-function-an-overview.","DOI":"10.7759\/cureus.19924"}],"container-title":["Critical Reviews in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/04a416af66c11560\/43-56.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T06:08:52Z","timestamp":1752300532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,71e03f7b7d3d9c9c,04a416af66c11560.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.2025057969","relation":{},"ISSN":["1040-8401"],"issn-type":[{"value":"1040-8401","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}